Media Summary: Costa Bachas, PhD, Amsterdam University Medical Center, Amsterdam, Netherlands, comments Sarah Holstein, MD, PhD, University of Nebraska Medical Center, Omaha, NE, maps out the future of measurable residual ... Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the key challenges and future of measurable residual ...

Implementing Computational Mrd Assessment Into - Detailed Analysis & Overview

Costa Bachas, PhD, Amsterdam University Medical Center, Amsterdam, Netherlands, comments Sarah Holstein, MD, PhD, University of Nebraska Medical Center, Omaha, NE, maps out the future of measurable residual ... Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the key challenges and future of measurable residual ... The virtual AML Hub Satellite Symposium at the 46th Annual Meeting of the European Society for Blood and Marrow ... ... of integrating molecular profiling and measurable residual disease ( Elias Jabbour, MD; Mark J. Levis, MD, PhD; Martin S. Tallman, MD; and Richard M. Stone, MD, discuss the status of

Graham Jackson, MBBS, FRCP, FRCPath, MD, Newcastle upon Tyne Hospitals NHS Trust, Newcastle, UK, discusses the ... Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, comments Jill Corre, PharmD, PhD, of L'Institut Universitaire du Cancer de Toulouse-Oncopole, Centre Hospitalier Universitaire, Toulouse, ...

Photo Gallery

Implementing computational MRD assessment into clinical practice: challenges and solutions
Translating MRD assessment into routine clinical practice
The key challenges and future of MRD assessment in multiple myeloma
New developments in molecular MRD assessment in AML
MRD assessment in AML: challenges and evolving clinical impact
Molecular profiling and MRD are reshaping transplant decision-making in AML
MRD Assessment and Consolidation in AML
Archive: MRD Monitoring in Acute Myeloid Leukemia
Depth of MRD assessment in MM
Improving the sensitivity of MRD assessment in AML: multi-omic characterization of progenitor cells
MRD Assessment and its Clinical Implications in AML
Measuring MRD: methods and challenges
View Detailed Profile
Implementing computational MRD assessment into clinical practice: challenges and solutions

Implementing computational MRD assessment into clinical practice: challenges and solutions

Costa Bachas, PhD, Amsterdam University Medical Center, Amsterdam, Netherlands, comments

Translating MRD assessment into routine clinical practice

Translating MRD assessment into routine clinical practice

Sarah Holstein, MD, PhD, University of Nebraska Medical Center, Omaha, NE, maps out the future of measurable residual ...

The key challenges and future of MRD assessment in multiple myeloma

The key challenges and future of MRD assessment in multiple myeloma

Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the key challenges and future of measurable residual ...

New developments in molecular MRD assessment in AML

New developments in molecular MRD assessment in AML

The virtual AML Hub Satellite Symposium at the 46th Annual Meeting of the European Society for Blood and Marrow ...

MRD assessment in AML: challenges and evolving clinical impact

MRD assessment in AML: challenges and evolving clinical impact

In

Molecular profiling and MRD are reshaping transplant decision-making in AML

Molecular profiling and MRD are reshaping transplant decision-making in AML

... of integrating molecular profiling and measurable residual disease (

MRD Assessment and Consolidation in AML

MRD Assessment and Consolidation in AML

Elias Jabbour, MD; Mark J. Levis, MD, PhD; Martin S. Tallman, MD; and Richard M. Stone, MD, discuss the status of

Archive: MRD Monitoring in Acute Myeloid Leukemia

Archive: MRD Monitoring in Acute Myeloid Leukemia

Minimal residual disease (

Depth of MRD assessment in MM

Depth of MRD assessment in MM

Graham Jackson, MBBS, FRCP, FRCPath, MD, Newcastle upon Tyne Hospitals NHS Trust, Newcastle, UK, discusses the ...

Improving the sensitivity of MRD assessment in AML: multi-omic characterization of progenitor cells

Improving the sensitivity of MRD assessment in AML: multi-omic characterization of progenitor cells

Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, comments

MRD Assessment and its Clinical Implications in AML

MRD Assessment and its Clinical Implications in AML

Experts expand

Measuring MRD: methods and challenges

Measuring MRD: methods and challenges

Jill Corre, PharmD, PhD, of L'Institut Universitaire du Cancer de Toulouse-Oncopole, Centre Hospitalier Universitaire, Toulouse, ...

Archive: AML MRD: Changing the Concept of Disease Remission

Archive: AML MRD: Changing the Concept of Disease Remission

MRD